UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2016

 

 

 

XOMA CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

(State or other jurisdiction of incorporation)

 

     
0-14710   52-2154066

(Commission

File Number)

  

(IRS Employer

Identification No.)

   
2910 Seventh Street, Berkeley, California   94710
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code (510) 204-7200

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Senior Vice President, Research and Development and Chief Medical Officer

 

On November 11, 2016, Dr. Paul Rubin, M.D., tendered his resignation as Senior Vice President, Research and Development and Chief Medical Officer of XOMA Corporation (“XOMA”). Dr. Rubin’s resignation is effective as of Friday, November 18, 2016. Dr. Rubin’s responsibilities will be assumed by Dr. Patrick J. Scannon, M.D., Ph.D., XOMA’s Executive Vice President and Chief Scientific Officer, and other current members of XOMA’s clinical, regulatory and medical teams.

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

             
Date:   November 11, 2016       XOMA CORPORATION
       
        By:    

/s/ Denis J. Quinlan

            Denis J. Quinlan
            Sr. Corporate Counsel & Corporate Secretary